{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:43:35Z","timestamp":1784958215025,"version":"3.55.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Dutch charity foundation KiKa"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"Abstract<\/jats:title>\n \n STUDY QUESTION<\/jats:title>\n What is the impact of the EuroNet-PHL-C2 treatment protocol for children with classical Hodgkin lymphoma (cHL) on gonadal function in girls, based on assessment of serum anti-M\u00fcllerian hormone (AMH)?<\/jats:p>\n <\/jats:sec>\n \n SUMMARY ANSWER<\/jats:title>\n Serum AMH levels decreased after induction chemotherapy and increased during subsequent treatment and 2\u2009years of follow-up, with lowest levels in patients treated for advanced stage cHL.<\/jats:p>\n <\/jats:sec>\n \n WHAT IS KNOWN ALREADY<\/jats:title>\n Treatment for cHL, particularly alkylating agents and pelvic irradiation, can be gonadotoxic and result in premature reduction of primordial follicles in females. The current EuroNet-PHL-C2 trial aims to reduce the use of radiotherapy in standard childhood cHL treatment, by intensifying chemotherapy. This study aims to assess the gonadotoxic effect of the EuroNet-PHL-C2 protocol.<\/jats:p>\n <\/jats:sec>\n \n STUDY DESIGN, SIZE, DURATION<\/jats:title>\n This international, prospective, multicenter cohort study is embedded in the EuroNet-PHL-C2 trial, an European phase-3 treatment study evaluating the efficacy of standard cHL treatment with OEPA-COPDAC-28 (OEPA: vincristine, etoposide, prednisone, and doxorubicin; COPDAC-28: cyclophosphamide, vincristine, prednisone, and dacarbazine) versus intensified OEPA-DECOPDAC-21 (DECOPDAC-21: COPDAC with additional doxorubicin and etoposide and 25% more cyclophosphamide) in a randomized setting. Participants were recruited between January 2017 and September 2021.<\/jats:p>\n <\/jats:sec>\n \n PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n Female patients aged \u226418\u2009years, treated according to the EuroNet-PHL-C2 protocol for cHL were recruited across 18 sites in the Netherlands, Belgium, Germany, Austria, and Czech Republic. All parents and patients (aged \u226512\u2009years old) provided written informed consent. Serum AMH levels and menstrual cycle characteristics were evaluated over time (at diagnosis, one to three times during treatment and 2 up to 5\u2009years post-diagnosis) and compared between treatment-levels (TL1, TL2, and TL3) and treatment-arms (OEPA-COPDAC-28 and OEPA-DECOPDAC-21). Serum samples obtained from patients after receiving pelvic radiotherapy were excluded from the main analyses.<\/jats:p>\n <\/jats:sec>\n \n MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n A total of 104 females, with median age at diagnosis of 15.6\u2009years (IQR 13.7; 17.0), were included in the analysis. Ninety-nine were (post)pubertal. Eighteen girls were diagnosed with an early stage of cHL (TL1) and 86 with intermediate or advanced stage disease (50 TL2 and 36 TL3, 66% received COPDAC-28 and 34% DECOPDAC-21). Five patients received pelvic radiotherapy. Median AMH level at diagnosis was 1.7 \u00b5g\/l (IQR 0.9; 2.7). After two courses of OEPA chemotherapy, AMH levels decreased substantially in all patients (98% &lt;0.5 \u00b5g\/l), followed by a significant increase during the consolidation treatment and follow-up. After 2\u2009years, 68% of patients reached their baseline AMH value, with overall median recovery of 129% (IQR 75.0; 208.9) compared to baseline measurement. Five patients (7%) had AMH &lt;0.5 \u00b5g\/l. In patients treated for advanced stage disease, AMH levels remained significantly lower compared to early- or intermediate stage disease, with median serum AMH of 1.3 \u00b5g\/l (IQR 0.8; 2.1) after 2\u2009years. Patients who received DECOPDAC-21 consolidation had lower AMH levels during treatment than patients receiving COPDAC-28, but the difference was no longer statistically significant at 2\u2009years post-diagnosis. Of the 35 postmenarchal girls who did not receive hormonal co-treatment, 19 (54%) experienced treatment-induced amenorrhea, two girls had persisting amenorrhea after 2\u2009years.<\/jats:p>\n <\/jats:sec>\n \n LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n The studied population comprises young girls with diagnosis of cHL often concurring with pubertal transition, during which AMH levels naturally rise. There was no control population, while the interpretation of AMH as a biomarker during childhood is complex. The state of cHL disease may affect AMH levels at diagnosis, potentially complicating assessment of AMH recovery as a comparison with baseline AMH. The current analysis included data up to 2\u20135\u2009years post-diagnosis.<\/jats:p>\n <\/jats:sec>\n \n WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n The current PANCARE guideline advises to use the cyclophosphamide-equivalent dose score (CED-score, as an estimation of cumulative alkylating agent exposure) with a cut-off of 6000\u2009mg\/m2 to identify females aged &lt;25\u2009years at high risk of infertility. All treatment-arms of the EuroNet-PHL-C2 protocol remain below this cut-off, and based on this guideline, girls treated for cHL should therefore be considered low-risk of infertility. However, although we observed an increase in AMH after chemotherapy, it should be noted that not all girls recovered to pre-treatment AMH levels, particularly those treated for advanced stages of cHL. It remains unclear how our measurements relate to age-specific expected AMH levels and patterns. Additional (long-term) data are needed to explore clinical reproductive outcomes of survivors treated according to the EuroNet-PHL-C2 protocol.<\/jats:p>\n <\/jats:sec>\n \n STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n The fertility add-on study was funded by the Dutch charity foundation KiKa (project 257) that funds research on all forms of childhood cancer. C.M-K., D.K., W.H.W., D.H., M.C., A.U., and A.B. were involved in the development of the EuroNet-PHL-C2 regimen. The other authors indicated no potential conflicts of interest.<\/jats:p>\n <\/jats:sec>\n \n TRIAL REGISTRATION NUMBER<\/jats:title>\n N\/A.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/humrep\/deae112","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T08:37:42Z","timestamp":1716626262000},"page":"1701-1711","source":"Crossref","is-referenced-by-count":6,"title":["The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-M\u00fcllerian Hormone"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-4678","authenticated-orcid":false,"given":"K C E","family":"Drechsel","sequence":"first","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam, The Netherlands"},{"name":"Department of Paediatric Haemato-Oncology, Princess M\u00e1xima Center for Pediatric Oncology , Utrecht, The Netherlands"},{"name":"Cancer Center Amsterdam, Treament and quality of life, Amsterdam UMC, Vrije Universiteit Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-0931","authenticated-orcid":false,"given":"S L","family":"Broer","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine & Gynecology, University Medical Center Utrecht , Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9042-2404","authenticated-orcid":false,"given":"F S","family":"Stoutjesdijk","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8870-6539","authenticated-orcid":false,"given":"E","family":"van Dulmen-den Broeder","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-1823","authenticated-orcid":false,"given":"A","family":"Beishuizen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haemato-Oncology, Princess M\u00e1xima Center for Pediatric Oncology , Utrecht, The Netherlands"},{"name":"Department of Haematology\/Oncology, Erasmus MC\u2014Sophia Children\u2019s Hospital , Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-5674","authenticated-orcid":false,"given":"W H","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Haematology\/Oncology, Royal Hospital for Sick Children , Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"K\u00f6rholz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Universit\u00e4tsklinikum Giessen und Marburg GmbH, Standort Giessen\u2014Zentrum f\u00fcr Kinderheilkunde und Jugendmedizin , Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-8665","authenticated-orcid":false,"given":"C","family":"Mauz-K\u00f6rholz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Universit\u00e4tsklinikum Giessen und Marburg GmbH, Standort Giessen\u2014Zentrum f\u00fcr Kinderheilkunde und Jugendmedizin , Giessen, Germany"},{"name":"Clinic for Paediatric and Adolescent Medicine, Medical Faculty of the Martin, Luther University of Halle , Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-1610","authenticated-orcid":false,"given":"D","family":"Hasenclever","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informatik, Statistik und Epidemiologie, Universit\u00e4t Leipzig , Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-588X","authenticated-orcid":false,"given":"M","family":"Cepelova","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Faculty Hospital Motol and 2nd Medical Faculty, Charles University , Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5644-424X","authenticated-orcid":false,"given":"A","family":"Uyttebroeck","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology, KU Leuven, UZ Leuven , Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Ronceray","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, St Anna Children's Hospital, Medical University of Vienna , Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-1020","authenticated-orcid":false,"given":"J W R","family":"Twisk","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-8475","authenticated-orcid":false,"given":"G J L","family":"Kaspers","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam, The Netherlands"},{"name":"Department of Paediatric Haemato-Oncology, Princess M\u00e1xima Center for Pediatric Oncology , Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-0795","authenticated-orcid":false,"given":"M A","family":"Veening","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Cancer Center Amsterdam, Emma Children\u2019s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam, The Netherlands"},{"name":"Department of Paediatric Haemato-Oncology, Princess M\u00e1xima Center for Pediatric Oncology , Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"2024080105572615400_deae112-B1","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/humrep\/den285","article-title":"Ovarian failure following cancer treatment: current management and quality of life","volume":"23","author":"Absolom","year":"2008","journal-title":"Hum Reprod"},{"key":"2024080105572615400_deae112-B2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/humupd\/dmac004","article-title":"Anti-M\u00fcllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review","volume":"28","author":"Anderson","year":"2022","journal-title":"Hum Reprod Update"},{"key":"2024080105572615400_deae112-B3","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin\u2019s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet Oncol"},{"key":"2024080105572615400_deae112-B4","doi-asserted-by":"crossref","first-page":"574263","DOI":"10.3389\/fendo.2020.574263","article-title":"The clinical value and interpretation of anti-M\u00fcllerian Hormone in women with cancer","volume":"11","author":"Anderson","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024080105572615400_deae112-B5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 Trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"key":"2024080105572615400_deae112-B6","doi-asserted-by":"crossref","first-page":"102035","DOI":"10.1016\/j.jogoh.2020.102035","article-title":"Evaluation of ovarian reserve before and after chemotherapy","volume":"50","author":"Berjeb","year":"2020","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2024080105572615400_deae112-B7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10815-015-0636-6","article-title":"Fertility in young patients following treatment for Hodgkin\u2019s lymphoma: a single center survey","volume":"33","author":"Bolte\u017ear","year":"2016","journal-title":"J Assist Reprod Genet"},{"key":"2024080105572615400_deae112-B8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/humupd\/dmu020","article-title":"Anti-M\u00fcllerian hormone: ovarian reserve testing and its potential clinical implications","volume":"20","author":"Broer","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2024080105572615400_deae112-B9","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1210\/jc.2011-3180","article-title":"Anti-M\u00fcllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: A prospective study","volume":"97","author":"Brougham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2024080105572615400_deae112-B10","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/humrep\/deab189","article-title":"Longitudinal study of AMH variations in 122 adolescents and young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling","volume":"36","author":"Decanter","year":"2021","journal-title":"Hum Reprod"},{"key":"2024080105572615400_deae112-B11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/humrep\/det442","article-title":"Decreased serum anti-M\u00fcllerian hormone levels in girls with newly diagnosed cancer","volume":"29","author":"Dorp","year":"2014","journal-title":"Hum Reprod"},{"key":"2024080105572615400_deae112-B12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/humupd\/dmad002","article-title":"Reproductive ability in survivors of childhood, adolescent and young adult Hodgkin lymphoma: a review","volume":"29","author":"Drechsel","year":"2023","journal-title":"Hum Reprod Update"},{"key":"2024080105572615400_deae112-B13","doi-asserted-by":"crossref","first-page":"13677","DOI":"10.1007\/s00432-023-05035-z","article-title":"Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma","volume":"149","author":"Drechsel","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024080105572615400_deae112-B14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpag.2016.02.009","article-title":"Low anti-M\u00fcllerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy","volume":"29","author":"Elchuri","year":"2016","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"2024080105572615400_deae112-B15","author":"European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL)","year":"2015"},{"key":"2024080105572615400_deae112-B17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/humrep\/den487","article-title":"Assessment of ovarian reserve in adult childhood cancer survivors using anti-M\u00fcllerian hormone","volume":"24","author":"Fong","year":"2009","journal-title":"Hum Reprod"},{"key":"2024080105572615400_deae112-B18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/pbc.24679","article-title":"The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study","volume":"61","author":"Green","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2024080105572615400_deae112-B19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/humrep\/der435","article-title":"Individual serum levels of anti-M\u00fcllerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study","volume":"27","author":"Hagen","year":"2012","journal-title":"Hum Reprod"},{"key":"2024080105572615400_deae112-B20","author":"IBM Corp","year":"2021"},{"key":"2024080105572615400_deae112-B21","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1210\/clinem\/dgaa172","article-title":"Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH","volume":"105","author":"Irene Su","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2024080105572615400_deae112-B22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.fertnstert.2015.11.020","article-title":"Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all","volume":"105","author":"Jacobson","year":"2016","journal-title":"Fertil Steril"},{"key":"2024080105572615400_deae112-B23","doi-asserted-by":"crossref","first-page":"e22024","DOI":"10.1371\/journal.pone.0022024","article-title":"A validated model of serum anti-M\u00fcllerian hormone from conception to menopause","volume":"6","author":"Kelsey","year":"2011","journal-title":"PLoS One"},{"key":"2024080105572615400_deae112-B24","doi-asserted-by":"crossref","first-page":"125080","DOI":"10.1155\/2013\/125080","article-title":"Anti-M\u00fcllerian hormone as a sensitive marker of ovarian function in young cancer survivors","volume":"2013","author":"Krawczuk-Rybak","year":"2013","journal-title":"Int J Endocrinol"},{"key":"2024080105572615400_deae112-B25","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.26403","article-title":"Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer","volume":"118","author":"Letourneau","year":"2012","journal-title":"Cancer"},{"key":"2024080105572615400_deae112-B26","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10815-012-9880-1","article-title":"Correlation between three assay systems for anti-M\u00fcllerian hormone (AMH) determination","volume":"29","author":"Li","year":"2012","journal-title":"J Assist Reprod Genet"},{"key":"2024080105572615400_deae112-B27","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1210\/jc.2012-1440","article-title":"Serum anti-M\u00fcllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood","volume":"97","author":"Lie Fong","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2024080105572615400_deae112-B28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","article-title":"Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol"},{"key":"2024080105572615400_deae112-B29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0303-7207(00)00365-8","article-title":"Reproduction post-chemotherapy in young cancer patients","volume":"169","author":"Meirow","year":"2000","journal-title":"Mol Cell Endocrinol"},{"key":"2024080105572615400_deae112-B30","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S1470-2045(20)30582-9","article-title":"Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024080105572615400_deae112-B31","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S1470-2045(20)30594-5","article-title":"Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024080105572615400_deae112-B32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1634\/theoncologist.2017-0201","article-title":"Ovarian and uterine functions in female survivors of childhood cancers","volume":"23","author":"Oktem","year":"2018","journal-title":"Oncologist"},{"key":"2024080105572615400_deae112-B34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10815-016-0675-7","article-title":"IVF results in patients with very low serum AMH are significantly affected by chronological age","volume":"33","author":"Revelli","year":"2016","journal-title":"J Assist Reprod Genet"},{"key":"2024080105572615400_deae112-B35","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"2024080105572615400_deae112-B36","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.3390\/ijms20215342","article-title":"The impact of chemotherapy on the ovaries: molecular aspects and the prevention of ovarian damage","volume":"20","author":"Sonigo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2024080105572615400_deae112-B37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dmz027","article-title":"Ovarian damage from chemotherapy and current approaches to its protection","volume":"25","author":"Spears","year":"2019","journal-title":"Hum Reprod Update"},{"key":"2024080105572615400_deae112-B38","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.fertnstert.2018.10.016","article-title":"Uterine function, pregnancy complications, and pregnancy outcomes among female childhood cancer survivors","volume":"111","author":"van de Loo","year":"2019","journal-title":"Fertil Steril"},{"key":"2024080105572615400_deae112-B39","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/humrep\/dey229","article-title":"Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve","volume":"33","author":"Van Den Berg","year":"2018","journal-title":"Human Reproduction"},{"key":"2024080105572615400_deae112-B40","first-page":"1451","article-title":"Pregnancy, time to pregnancy and obstetric outcomes among female childhood cancer survivors: results of the DCOG LATER-VEVO study","volume":"146","author":"van Dijk","year":"2020","journal-title":"J Res Clin Oncol"},{"key":"2024080105572615400_deae112-B41","doi-asserted-by":"crossref","first-page":"e8772","DOI":"10.1371\/journal.pone.0008772","article-title":"Human ovarian reserve from conception to the menopause","volume":"5","author":"Wallace","year":"2010","journal-title":"PLoS One"},{"key":"2024080105572615400_deae112-B42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/humrep\/deg016","article-title":"The radiosensitivity of the human oocyte","volume":"18","author":"Wallace","year":"2003","journal-title":"Hum Reprod"},{"key":"2024080105572615400_deae112-B43","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2004.11.038","article-title":"Predicting age of ovarian failure after radiation to a field that includes the ovaries","volume":"62","author":"Wallace","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024080105572615400_deae112-B44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/humrep\/dew027","article-title":"ESHRE guideline: management of women with premature ovarian insufficiency","volume":"31","author":"Webber","year":"2016","journal-title":"Hum Reprod"},{"key":"2024080105572615400_deae112-B45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0004563219830733","article-title":"Paediatric reference intervals for plasma anti-M\u00fcllerian hormone: comparison of data from the Roche Elecsys assay and the Beckman Coulter Access assay using the same cohort of samples","volume":"56","author":"Yates","year":"2019","journal-title":"Ann Clin Biochem"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/8\/1701\/58673518\/deae112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/8\/1701\/58673518\/deae112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T08:34:07Z","timestamp":1722501247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/39\/8\/1701\/7682021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,5,24]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deae112","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,5,24]]}}}